Konyn P, Ahmed A, Kim D. Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2021, 15: 1295-1307.

Strand NH, Hagedorn JM, Dunn T, Johnson B, Abd-Elsayed A, Covington S, et al. Advances in radiofrequency ablation: mechanism of action and technology. Ann Palliat Med. 2024, 13: 1028-1034.

Chen L, Sun J, Yang X. Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status. Cancer Lett. 2016, 370: 78-84.

Wu X, Lokken RP, Mehta N. Optimal treatment for small HCC (<3 cm): Resection, liver transplantation, or locoregional therapy? JHEP Rep. 2023, 5: 100781.

Salmi A, Turrini R, Lanzani G, Viviani G, Zappella A, Savio A, et al. Long-term effectiveness of radiofrequency ablation for hepatocellular carcinoma of 3.5 cm or less. Hepatogastroenterology. 2008, 55: 191-196.

Zhao Z, Wu J, Liu X, Liang M, Zhou X, Ouyang S, et al. Insufficient radiofrequency ablation promotes proliferation of residual hepatocellular carcinoma via autophagy. Cancer Lett. 2018, 421: 73-81.

Zhang N, Ma D, Wang L, Zhu X, Pan Q, Zhao Y, et al. Insufficient Radiofrequency Ablation Treated Hepatocellular Carcinoma Cells Promote Metastasis by Up-Regulation ITGB3. J Cancer. 2017, 8: 3742-3754.

Feng Y, He X, Yang Y, Chao D, Lazarus LH, Xia Y. Current research on opioid receptor function. Curr Drug Targets. 2012, 13: 230-246.

Lennon FE, Mirzapoiazova T, Mambetsariev B, Poroyko VA, Salgia R, Moss J, et al. The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One. 2014, 9: e91577.

Lu H, Zhang H, Weng ML, Zhang J, Jiang N, Cata JP, et al. Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer. J Cell Physiol. 2021, 236: 4445-4454.

Li Y, Li G, Tao T, Kang X, Liu C, Zhang X, et al. The μ-opioid receptor (MOR) promotes tumor initiation in hepatocellular carcinoma. Cancer Lett. 2019, 453: 1-9.

Zhang H, Zhou D, Gu J, Qu M, Guo K, Chen W, et al. Targeting the mu-Opioid Receptor for Cancer Treatment. Curr Oncol Rep. 2021, 23: 111.

Ramirez MF, Gorur A, Cata JP. Opioids and cancer prognosis: A summary of the clinical evidence. Neurosci Lett. 2021, 746: 135661.

Kong J, Pan B, Ke S, Dong S, Li X, Zhou A, et al. Insufficient radiofrequency ablation promotes angiogenesis of residual hepatocellular carcinoma via HIF-1α/VEGFA. PLoS One. 2012, 7: e37266.

Zhang N, Li H, Qin C, Ma D, Zhao Y, Zhu W, et al. Insufficient radiofrequency ablation promotes the metastasis of residual hepatocellular carcinoma cells via upregulating flotillin proteins. J Cancer Res Clin Oncol. 2019, 145: 895-907.

Tan Y, Zhao L. miR-103 promotes hepatocellular carcinoma cell proliferation and migration in the simulation transition zone of RFA through PI3K/Akt signaling pathway by targeting PTEN. Int J Clin Exp Pathol. 2020, 13: 473-479.

Li G, Kong J, Dong S, Niu H, Wu S, Sun W. Circular BANP knockdown inhibits the malignant progression of residual hepatocellular carcinoma after insufficient radiofrequency ablation. Chin Med J (Engl). 2022, 135: 1578-1587.

Zhou HQ, Liu MS, Deng TB, Xie PB, Wang W, Shao T, et al. The TGF-β/Smad Pathway Inhibitor SB431542 Enhances The Antitumor Effect Of Radiofrequency Ablation On Bladder Cancer Cells. Onco Targets Ther. 2019, 12: 7809-7821.

Song Y, Bi Z, Liu Y, Qin F, Wei Y, Wei X. Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials. Genes Dis. 2022, 10: 76-88.

Li L, Zhao GD, Shi Z, Qi LL, Zhou LY, Fu ZX. The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC. Oncol Lett. 2016, 12: 3045-3050.

Deng Q, He M, Fu C, Feng K, Ma K, Zhang L. Radiofrequency ablation in the treatment of hepatocellular carcinoma. Int J Hyperthermia. 2022, 39: 1052-1063.

Guo Y, Ren Y, Dong X, Kan X, Zheng C. An Overview of Hepatocellular Carcinoma After Insufficient Radiofrequency Ablation. J Hepatocell Carcinoma. 2022, 9: 343-355.

Jia G, Li F, Tong R, Liu Y, Zuo M, Ma L, et al. c-Met/MAPK pathway promotes the malignant progression of residual hepatocellular carcinoma cells after insufficient radiofrequency ablation. Med Oncol. 2020, 37: 117.

Su T, Huang M, Liao J, Lin S, Yu P, Yang J, et al. Insufficient Radiofrequency Ablation Promotes Hepatocellular Carcinoma Metastasis Through N6-Methyladenosine mRNA Methylation-Dependent Mechanism. Hepatology. 2021, 74: 1339-1356.

Ikemoto T, Shimada M, Yamada S. Pathophysiology of recurrent hepatocellular carcinoma after radiofrequency ablation. Hepatol Res. 2017, 47: 23-30.

Xiong B, Li C, Hong G, Li J, Luo Q, Gong J, et al. HMGB1/TREM1 crosstalk between heat-injured hepatocytes and macrophages promotes HCC progression after RFA. J Cancer Res Clin Oncol. 2024, 150: 480.

Ramirez MF, Gorur A, Cata JP. Opioids and cancer prognosis: A summary of the clinical evidence. Neurosci Lett. 2021, 746: 135661.

Novy DM, Nelson DV, Koyyalagunta D, Cata JP, Gupta P, Gupta K. Pain, opioid therapy, and survival: a needed discussion. Pain. 2020, 161: 496-501.

Lennon FE, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, Singleton PA. Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology. 2012, 116: 857-867.

Zhang M, Su J, Zhang Y, Xu J, Zhang S. Conveying endogenous and exogenous signals: MAPK cascades in plant growth and defense. Curr Opin Plant Biol. 2018, 45(Pt A): 1-10.

Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002, 12: 9-18.

Chen C, Nelson LJ, Ávila MA, Cubero FJ. Mitogen-Activated Protein Kinases (MAPKs) and Cholangiocarcinoma: The Missing Link. Cells. 2019, 8: 1172.

Timofeev O, Giron P, Lawo S, Pichler M, Noeparast M. ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework. NPJ Precis Oncol. 2024, 8: 70.

Pan X, Pei J, Wang A, Shuai W, Feng L, Bu F, et al. Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy. Acta Pharm Sin B. 2022, 12: 2171-2192.